Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

Exclusion Criteria

• •Newly diagnosed patients older than age 55 who:
• •* Refuse chemotherapy when their treating physician recommends standard anti-leukemia induction chemotherapy.
• •* Have a Karnofsky performance status of greater or equal to 70%, aged \< 75 years and has no prior myelodysplastic syndrome.
• •* Have a risk/benefit ratio that gives their treating physician good reason for administration of standard anti-leukemia induction chemotherapy.
• •Patients who have already been treated with arsenics.
• •CML in blastic crisis.
• •Patients with cardiopathies including recurrent supraventricular arrhythmia and any type of sustained ventricular arrhythmia or conduction block (A-V block grade II or III, LBBB).
• •Patients with HIV.
• •Pregnant or breastfeeding women.
• •QT interval \> 460 msec in the presence of serum potassium \> 4.0 mEq/L and magnesium \> 1.8 mg/dL.
• •Pre-existing neurotoxicity/neuropathy of Grade 2 or greater according to the NCI Common Toxicity Criteria Version 2.
• •History of preexisting neurological disorders (grade 3 or higher by the NCI Common Toxicity Criteria; in particular, seizure disorders).
• •Patients with an underlying medical condition that could be aggravated by the treatment or life threatening disease unrelated to AML as evaluated by the enrolling physician.
• •Patients with active second malignancy, excluding adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
• •Inability or unwillingness to comply with the treatment protocol.